

Update to the step therapy program

For dates of service on or after 10/1/2025, the following drugs will be added to the program as non-preferred agents:

Requested product	Preferred alternative agent(s)	Special comments
Jobevne (bevacizumab-nwgd) (J9999) <i>*for oncology indications only</i>	Mvasi (bevacizumab-awwb) (Q5107) Zirabev (bevacizumab-bvzr) (Q5118)	
Soliris (eculizumab) (J1299) Bkemv (eculizumab-aeeb) (Q5152)	Epysqli (eculizumab-aagh) (Q5151) AND Ultomiris (ravulizumab-cwvz) (J1303)	For Medicare members and indication of <i>Neuromyelitis Optica Spectrum Disorder (NMOSD)</i>, the patient has had a clinical trial, inadequate response, or contraindication to Ultomiris (ravulizumab-cwvz) only For all other indications and lines of business, Ultomiris (ravulizumab-cwvz) AND Epysqli (eculizumab-aagh) are required

In-scope indications include all medically accepted indications. These **step therapy requirements** apply to Medicare, individual and family, small and large employer group plans, as well as select Security Administrative Services groups managed by Prime Therapeutics, unless otherwise noted in the table above. Preferred biosimilars may differ based on the line of business.

Implementation of these **step therapy criteria** will be for new starts only (no use in the previous 365 days), meaning no beneficiaries currently receiving eligible step therapy drugs will have to change their drug. Please note, prior authorization criteria may still apply to these medications. Step therapy and prior authorization will be managed through Security Health Plan's specialty pharmacy medication partner, Prime Therapeutics. Please call 1-800-424-8243 or visit their website for details.